Ausbil Investment Management Ltd Has $1.23 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Ausbil Investment Management Ltd decreased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 63.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 13,246 shares of the medical instruments supplier’s stock after selling 22,740 shares during the period. Ausbil Investment Management Ltd’s holdings in LeMaitre Vascular were worth $1,230,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after acquiring an additional 38,303 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of LeMaitre Vascular by 4.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,858 shares of the medical instruments supplier’s stock worth $673,000 after purchasing an additional 555 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in shares of LeMaitre Vascular by 18.6% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,342 shares of the medical instruments supplier’s stock valued at $421,000 after acquiring an additional 993 shares during the last quarter. Chatham Capital Group Inc. boosted its position in shares of LeMaitre Vascular by 21.7% during the first quarter. Chatham Capital Group Inc. now owns 49,229 shares of the medical instruments supplier’s stock worth $3,267,000 after purchasing an additional 8,770 shares in the last quarter. Finally, Congress Wealth Management LLC DE increased its holdings in shares of LeMaitre Vascular by 27.8% in the first quarter. Congress Wealth Management LLC DE now owns 98,986 shares of the medical instruments supplier’s stock worth $6,569,000 after acquiring an additional 21,532 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Price Performance

LMAT stock traded down $0.28 during midday trading on Thursday, reaching $86.69. 22,594 shares of the stock were exchanged, compared to its average volume of 121,562. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $93.32. The company has a fifty day moving average price of $89.22 and a 200 day moving average price of $81.97. The stock has a market capitalization of $1.95 billion, a PE ratio of 57.60, a P/E/G ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The firm’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.37 earnings per share. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.74%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Analyst Ratings Changes

A number of equities analysts have issued reports on LMAT shares. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Barrington Research reissued an “outperform” rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research report on Friday, September 20th. JMP Securities boosted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Finally, Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average target price of $94.67.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.